Base de dados : MEDLINE
Pesquisa : D01.268.558.362.984 [Categoria DeCS]
Referências encontradas : 487 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 49 ir para página                         

  1 / 487 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745365
[Au] Autor:Li Q; Wang Z; Chen Y; Zhang G
[Ad] Endereço:Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, P. R. China. wangzheng@mail.sic.ac.cn.
[Ti] Título:Elemental bio-imaging of PEGylated NaYF :Yb/Tm/Gd upconversion nanoparticles in mice by laser ablation inductively coupled plasma mass spectrometry to study toxic side effects on the spleen, liver and kidneys.
[So] Source:Metallomics;9(8):1150-1156, 2017 Aug 16.
[Is] ISSN:1756-591X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Rare-earth upconversion nanoparticles (UCNPs) are considered stable nanoprobes with low toxicity and deep tissue penetration. However, the increasing use of UCNPs has raised concerns about their potential toxicity in living organisms. Very few studies have reported the toxicity of UCNPs; hence, it is not possible to conclude yet that UCNPs are safe. In this study, the distribution of PEGylated NaYF :Yb/Tm/Gd nanoparticles (PEG-UCNPs) in female Balb/c mice following intravenous administration, and imaging in the spleen, liver and kidney was examined by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). PEG-UCNPs distributed primarily to the liver and spleen, with significant but lower levels being noted in the kidneys, heart, and lungs. At the sub-organ level, PEG-UCNPs mainly accumulated within the red pulp of the spleen instead of the white pulp, which indicated that PEG-UCNPs are poorly immunogenic, or not immunogenic at all. The imaging of Cu in the liver and spleen showed that the primary clearance organ for PEG-UCNPs is the liver, although they are accumulated in the spleen rather than the liver. This can be explained by the fact that excess superoxide anions produced by phagocytosis of the PEG-UCNPs need Cu-Zn-superoxide dismutase to be converted to hydrogen peroxide. From the Fe, Cu, and Zn imaging of the kidney, it was concluded that PEG-UCNPs do not exhibit nephrotoxicity.
[Mh] Termos MeSH primário: Rim/efeitos dos fármacos
Fígado/efeitos dos fármacos
Imagem Molecular/métodos
Nanopartículas/toxicidade
Polietilenoglicóis/química
Baço/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Feminino
Fluoretos/química
Fluoretos/farmacocinética
Gadolínio/química
Gadolínio/farmacocinética
Rim/metabolismo
Terapia a Laser
Fígado/metabolismo
Espectrometria de Massas
Camundongos
Camundongos Endogâmicos BALB C
Nanopartículas/química
Baço/metabolismo
Túlio/química
Túlio/farmacocinética
Distribuição Tecidual
Itérbio/química
Itérbio/farmacocinética
Ítrio/química
Ítrio/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
30IQX730WE (Polyethylene Glycols); 58784XQC3Y (Yttrium); 8RKC5ATI4P (Thulium); AU0V1LM3JT (Gadolinium); MNQ4O4WSI1 (Ytterbium); Q80VPU408O (Fluorides)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171229
[Lr] Data última revisão:
171229
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1039/c7mt00132k


  2 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28421294
[Au] Autor:Sun F; Zhao R; Zhu Y; Cui D; Wang X; Han B; Liang S; Liu H; Sun X; Zhao F; Xu D; Xia S
[Ad] Endereço:Shanghai General Hospital, Shanghai, China.
[Ti] Título:A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
[So] Source:Cancer Chemother Pharmacol;79(6):1099-1107, 2017 Jun.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Objective To compare intra-arterial chemotherapy combined with intravesical chemotherapy with intravesical chemotherapy alone in the treatment of high-risk non-muscle invasive bladder cancer (HRBC) after thulium laser resection of a bladder tumor (TmLRBT). MATERIALS AND METHODS: From January 2009 to December 2013, 283 patients with HRBC were randomly assigned to the combined group (group A, n = 141) or intravesical chemotherapy-alone group (group B, n = 142) after TmLRBT. Intra-arterial chemotherapy was administered after initial TmLRBT, with 3 courses at 4-week intervals. Each course consisted of cisplatin (50 mg/m ) and epirubicin (30 mg/m ). Intravesical chemotherapy was administered in both groups, including an immediate 50 mg of epirubicin instillation after TmLRBT and weekly maintenance for 8 weeks, followed by monthly maintenance for 1 year. RESULTS: The recurrence rate was 29.1% (41/141) in group A and 42.9% (61/142) in group B, with a significant difference (p = 0.01). The progression rate was 15.6% (22/141) in group A and 25.3% (36/142) in group B, with a significant difference (p = 0.039). Patients with concomitant carcinoma in situ (CIS) also had a lower recurrence rate and progression rate in group A compared to those in group B (p = 0.006 and p = 0.03, respectively). On univariate and multivariate logistic regression analyses, patients with low-grade histology had a higher reccurrence-free rate. Multivariate COX analysis of tumor-related factors suggested that concomitant CIS was the only significant prognostic factor associated with poorer recurrence-free survival and progression-free survival. CONCLUSIONS: Intra-arterial chemotherapy combined with intravesical chemotherapy could reduce the risk of recurrence and progression compared to intravesical chemotherapy alone in HRBC.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Terapia a Laser/métodos
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Administração Intravesical
Idoso
Idoso de 80 Anos ou mais
Antibióticos Antineoplásicos/administração & dosagem
Antineoplásicos/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cisplatino/administração & dosagem
Terapia Combinada
Cistectomia
Intervalo Livre de Doença
Epirubicina/administração & dosagem
Feminino
Seres Humanos
Injeções Intra-Arteriais
Masculino
Meia-Idade
Recidiva Local de Neoplasia/epidemiologia
Prognóstico
Estudos Prospectivos
Túlio
Neoplasias da Bexiga Urinária/diagnóstico por imagem
Neoplasias da Bexiga Urinária/cirurgia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 0 (Antineoplastic Agents); 3Z8479ZZ5X (Epirubicin); 8RKC5ATI4P (Thulium); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-017-3305-x


  3 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28168722
[Au] Autor:Wang XJ; Zhuo J; Luo GH; Zhu YP; Yu DJ; Zhao RZ; Jiang CY; Shi YF; Li H; Chen L; Hao KY; Han X; Zhao S; Bei XY; Jing YF; Xia SJ
[Ad] Endereço:Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[Ti] Título:Androgen Deprivation Accelerates the Prostatic Urethra Wound Healing After Thulium Laser Resection of the Prostate by Promoting Re-Epithelialization and Regulating the Macrophage Polarization.
[So] Source:Prostate;77(7):708-717, 2017 May.
[Is] ISSN:1097-0045
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Complications after a thulium laser resection of the prostate (TmLRP) are related to re-epithelialization of the prostatic urethra. Since prostate growth and development are induced by androgen, the aim of this study was to determine the role and explore the mechanism of androgen in wound healing of the prostatic urethra. METHODS: Beagles that received TmLRPs were randomly distributed into a castration group, a testosterone undecanoate (TU) group, and a control group. The prostate wound was assessed once a week using a cystoscope. Histological analysis was then carried out to study the re-epithelialization of the prostatic urethra in each group. The inflammatory response in the wound tissue and urine was also investigated. RESULTS: The healing of the prostatic urethra after a TmLRP was more rapid in the castration group and slower in the TU group than that in the control group. Castration accelerated re-epithelialization by promoting basal cell proliferation in the wound surface and beneath the wound and by accelerating the differentiation of basal cells into urothelial cells. Castration reduced the duration of the inflammatory phase and induced the conversion of M1 macrophages to M2 macrophages, thus accelerating the maturation of the wound. By contrast, androgen supplementation enhanced the inflammatory response and prolonged the inflammatory phase. Moreover, the anti-inflammatory phase was delayed and weakened. CONCLUSION: Androgen deprivation promotes re-epithelialization of the wound, regulates the inflammatory response, and accelerates wound healing of the prostatic urethra after a TmLRP. Prostate 77:708-717, 2017. © 2017 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Androgênios
Complicações Intraoperatórias
Próstata
Testosterona/análogos & derivados
Ressecção Transuretral da Próstata/efeitos adversos
Uretra
[Mh] Termos MeSH secundário: Androgênios/administração & dosagem
Androgênios/efeitos adversos
Androgênios/metabolismo
Animais
Modelos Animais de Doenças
Cães
Complicações Intraoperatórias/metabolismo
Complicações Intraoperatórias/fisiopatologia
Complicações Intraoperatórias/terapia
Macrófagos/patologia
Macrófagos/fisiologia
Masculino
Próstata/patologia
Próstata/cirurgia
Reepitelização/efeitos dos fármacos
Reepitelização/fisiologia
Estatística como Assunto
Testosterona/administração & dosagem
Testosterona/efeitos adversos
Testosterona/metabolismo
Túlio/farmacologia
Ressecção Transuretral da Próstata/métodos
Uretra/lesões
Uretra/patologia
Cicatrização/efeitos dos fármacos
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 3XMK78S47O (Testosterone); 8RKC5ATI4P (Thulium); H16A5VCT9C (testosterone undecanoate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE
[do] DOI:10.1002/pros.23301


  4 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28156134
[Au] Autor:Müllhaupt G; Abt D; Mordasini L; Köhle O; Engeler DS; Lüthi A; Sauter R; Schmid HP; Schwab C
[Ad] Endereço:1 Department of Urology, Cantonal Hospital St. Gallen , St. Gallen, Switzerland .
[Ti] Título:Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate.
[So] Source:J Endourol;31(4):380-383, 2017 Apr.
[Is] ISSN:1557-900X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the prevalence and extent of irrigation fluid absorption during thulium laser vaporization of the prostate. MATERIAL AND METHODS: Fifty-four patients undergoing thulium laser vaporization of the prostate were prospectively included into the trial at a tertiary referral center. Isotonic saline containing 1% ethanol was used for intraoperative irrigation. Absorption of irrigation fluid was measured periodically during the operation using the expired breath ethanol technique. Among others, intra- and postoperative changes in biochemical and hematological laboratory findings were assessed. RESULTS: Absorption of irrigation fluid was detected in 7 out of 54 (13%) patients with a median absorption volume of 265 mL (227-615). No significant differences of intra- and postoperative blood parameters were observed between absorbers and nonabsorbers. No risk factor (i.e., age, prostate size, surgery duration, applied energy, and amount of irrigation fluid) for the occurrence of fluid absorption could be identified. CONCLUSION: Absorption of irrigation fluid also occurs during thulium laser vaporization of the prostate and should be kept in mind, especially in patients at a high cardiovascular risk. However, compared with previously assessed resection and vaporization techniques, thulium vaporization might have a favorable safety profile regarding fluid absorption.
[Mh] Termos MeSH primário: Etanol/metabolismo
Terapia a Laser/métodos
Próstata/cirurgia
Cloreto de Sódio/metabolismo
Irrigação Terapêutica/métodos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Testes Respiratórios
Doenças Cardiovasculares
Etanol/análise
Seres Humanos
Masculino
Meia-Idade
Complicações Pós-Operatórias/epidemiologia
Estudos Prospectivos
Fatores de Risco
Túlio
Volatilização
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3K9958V90M (Ethanol); 451W47IQ8X (Sodium Chloride); 8RKC5ATI4P (Thulium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170602
[Lr] Data última revisão:
170602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170204
[St] Status:MEDLINE
[do] DOI:10.1089/end.2016.0888


  5 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28107762
[Au] Autor:Tontini GE; Neumann H; Pastorelli L; Spina L; Cavallaro F; Soriani P; Rimondi A; Bruni B; Clemente C; Fagnani F; Lagoussis P; Carmignani L; Vecchi M
[Ad] Endereço:Gastroenterology and Digestive Endoscopy Unit, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
[Ti] Título:Thulium laser in interventional endoscopy: animal and human studies.
[So] Source:Endoscopy;49(4):365-370, 2017 Apr.
[Is] ISSN:1438-8812
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The thulium laser system (TLS) is an emerging surgical tool. The 2-µm wavelength provides a confined coagulation depth (0.2 - 0.4 mm) to reduce the potential for inadvertent injuries. For the first time ever, we assessed TLS feasibility for endoscopic hemostasis ex vivo in pigs. In addition, we performed the first in vivo hemostatic treatments in humans. Tissue damage induced by TLS using different settings and optical fibers was compared to that from argon plasma coagulation (APC) in established ex vivo animal models. Three consecutive patients with complex nonvariceal upper gastrointestinal bleedings were treated and followed up. No deep submucosal injury was observed in animal models. The TLS showed a progressive penetration depth with increased power outputs and tissue exposures but very limited vertical tissue injury (0.1 - 2.0 mm) and lateral spreading damage (0.1 - 0.3 mm and 0.2 - 0.7 mm using the 365-µm and 550-µm fibers, respectively). In vivo, endoscopic hemostasis with TLS was always successful without complications. The TLS has proven to be very precise and easy to use. This novel technique appears to be a promising tool for advanced interventional endoscopy.
[Mh] Termos MeSH primário: Hemorragia Gastrointestinal/terapia
Hemostase Endoscópica/métodos
Lasers de Estado Sólido/uso terapêutico
Neoplasias Peritoneais/complicações
Túlio
[Mh] Termos MeSH secundário: Idoso
Animais
Coagulação com Plasma de Argônio
Úlcera Duodenal/complicações
Endoscopia do Sistema Digestório
Estudos de Viabilidade
Ectasia Vascular Gástrica Antral/complicações
Ectasia Vascular Gástrica Antral/terapia
Mucosa Gástrica
Hemorragia Gastrointestinal/etiologia
Hemostase Endoscópica/efeitos adversos
Hemostase Endoscópica/instrumentação
Seres Humanos
Terapia a Laser/instrumentação
Lasers de Estado Sólido/efeitos adversos
Masculino
Meia-Idade
Úlcera Péptica Hemorrágica/etiologia
Úlcera Péptica Hemorrágica/terapia
Neoplasias Peritoneais/patologia
Suínos
[Pt] Tipo de publicação:CASE REPORTS; COMPARATIVE STUDY; JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
8RKC5ATI4P (Thulium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE
[do] DOI:10.1055/s-0042-122014


  6 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28072622
[Au] Autor:Das T; Shinto A; Kamaleshwaran KK; Banerjee S
[Ad] Endereço:From the *Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, India; †Homi Bhabha National Institute, Anushaktinagar, Mumbai; ‡Department of Nuclear Medicine and PET, Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu; and §Radiation Medicine Centre, Bhabha Atomic Research Centre, Trombay, Mumbai, India.
[Ti] Título:170Tm-EDTMP: A Prospective Alternative of 89SrCl2 for Theranostic Treatment of Metastatic Bone Pain.
[So] Source:Clin Nucl Med;42(3):235-236, 2017 Mar.
[Is] ISSN:1536-0229
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We have earlier reported the potential of Tm-EDTMP as an alternative cost-effective radiopharmaceutical of SrCl2 for bone pain palliation application. Encouraging results obtained in the radiochemical studies and biological evaluations in animal model have prompted us to initiate the clinical study to evaluate the potential of Tm-EDTMP in human cancer patients. The serial scintigraphic images represent the whole-body scans of a patient (68 years old woman) with skeletal metastases of carcinoma of the breast origin recorded after administering 370 MBq (10 mCi) of Tm-EDTMP at different post-administration time points along with the pre-therapy images recorded with Tc-MDP in the same patient.
[Mh] Termos MeSH primário: Neoplasias Ósseas/diagnóstico por imagem
Neoplasias da Mama/diagnóstico por imagem
Dor do Câncer/diagnóstico por imagem
Carcinoma/diagnóstico por imagem
Compostos Organometálicos
Organofosfonatos
Compostos Radiofarmacêuticos
[Mh] Termos MeSH secundário: Idoso
Neoplasias Ósseas/secundário
Neoplasias da Mama/patologia
Carcinoma/patologia
Feminino
Seres Humanos
Túlio
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (170Tm-ethylenediamine-tetramethylenephosphonic acid); 0 (Organometallic Compounds); 0 (Organophosphonates); 0 (Radiopharmaceuticals); 8RKC5ATI4P (Thulium)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[St] Status:MEDLINE
[do] DOI:10.1097/RLU.0000000000001530


  7 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27987738
[Au] Autor:Yan H; Chen X; Shi J; Shi Z; Sun W; Lin Q; Wang X; Dai Z
[Ad] Endereço:College of Chemistry and Chemical Engineering, Hainan Normal University, Haikou 571100, China.
[Ti] Título:Fabrication and evaluation of chitosan/NaYF :Yb /Tm upconversion nanoparticles composite beads based on the gelling of Pickering emulsion droplets.
[So] Source:Mater Sci Eng C Mater Biol Appl;71:51-59, 2017 Feb 01.
[Is] ISSN:1873-0191
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The rare earth ion doped upconversion nanoparticles (UCNPs) synthesized by hydrophobic organic ligands possess poor solubility and low fluorescence quantum yield in aqueous media. To conquer this issue, NaYF :Yb /Tm UCNPs, synthesized by a hydrothermal method, were coated with F127 and then assembled with chitosan to fabricate the chitosan/NaYF :Yb /Tm composite beads (CS/NaYF :Yb /Tm CBs) by Pickering emulsion system. The characterization results revealed that the as-synthesized NaYF :Yb /Tm UCNPs with an average size of 20nm exhibited spherical morphology, high crystallinity and characteristic emission upconversion fluorescence with an overall blue color output. The NaYF :Yb /Tm UCNPs were successfully conjugated on the surface of chitosan beads by the gelling of emulsion droplets. The resultant CS/NaYF :Yb /Tm CBs showed good upconversion luminescent property, drug-loading capacity, release performance and excellent biocompatibility, exhibiting great potentials in targeted drug delivery and tissue engineering with potential tracking capability and lasting release performance.
[Mh] Termos MeSH primário: Quitosana/química
Fluoretos/química
Nanopartículas/química
Túlio/química
Itérbio/química
Ítrio/química
[Mh] Termos MeSH secundário: Avaliação Pré-Clínica de Medicamentos
Emulsões
Nanopartículas/ultraestrutura
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Emulsions); 0 (sodium yttriumtetrafluoride); 58784XQC3Y (Yttrium); 8RKC5ATI4P (Thulium); 9012-76-4 (Chitosan); MNQ4O4WSI1 (Ytterbium); Q80VPU408O (Fluorides)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161219
[St] Status:MEDLINE


  8 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27323703
[Au] Autor:R Kadukar M; Dhoble SJ; Sahu AK; Nayar V; Sailaja S; Reddy BS
[Ad] Endereço:Department of Physics, R.T.M.Nagpur University, Nagpur, 440033, Maharashtra, India.
[Ti] Título:Luminescence analysis of SrGa Si O : RE (RE = Dy, Tm) phosphors.
[So] Source:Luminescence;32(2):159-170, 2017 Mar.
[Is] ISSN:1522-7243
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This article reports on the luminescence properties of rare earth (Dy and Tm )ions doped SrGa Si O phosphor were studied. SrGa Si O phosphors weresynthesizedby employing solid state reaction method.From the measured X-ray diffraction (XRD) pattern of the samplemonoclinic phase structure has been observed. Thermoluminescenceand Mechanoluminescence properties of the γ-ray irradiated samples have been studied. Photoluminescence spectra of Dy activated SrGa Si O phosphor has been measured with an excitation wavelength at 348 nm,and it shows two emission bands at 483 and 574 nm due to F  â†’  H and F  â†’  H transitions respectively. Whereas the photoluminescence spectra of Tm activated SrGa Si O phosphor has been measured with an excitation wavelength at 359 nm and it exhibits two emission bands at 454 and 472 nm due to D  â†’  F and G  â†’  H transitions respectively. In thermoluminescence study, γ-irradiatedthermoluminescence glow curve of SrGa Si O :Dy phosphor shows two well defined peaks at 293 °C (peak1)and 170 °C (peak2) whereas thermoluminescence glow curve of SrGa Si O :Tm phosphor shows peaks at 292 °C (peak1) and 184 °C (peak2) indicating that two sets of traps are being activated within the particular temperature range and the trapping parameters associated with the prominent glow peaks of SrGa Si O :Dy and SrGa Si O :Tm are calculated using Chen's peak shape and initial rise method.From the Mechanoluminescence study, only one glow peak has been observed. Copyright © 2016 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Disprósio/análise
Gálio/análise
Luminescência
Oxigênio/análise
Estrôncio/análise
Túlio/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1D4N45714Q (Dysprosium); 8RKC5ATI4P (Thulium); CH46OC8YV4 (Gallium); S88TT14065 (Oxygen); YZS2RPE8LE (Strontium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160622
[St] Status:MEDLINE
[do] DOI:10.1002/bio.3161


  9 / 487 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26732107
[Au] Autor:Zhuo J; Wei HB; Zhang F; Liu HT; Zhao FJ; Han BM; Sun XW; Xia SJ; Jun-Lu
[Ad] Endereço:Department of Urology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China.
[Ti] Título:Two-micrometer thulium laser resection of the prostate-tangerine technique in benign prostatic hyperplasia patients with previously negative transrectal prostate biopsy.
[So] Source:Asian J Androl;19(2):244-247, 2017 Mar-Apr.
[Is] ISSN:1745-7262
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:The 2-µm thulium laser resection of the prostate-tangerine technique (TmLRP-TT) has been introduced as a minimally invasive treatment for benign prostatic hyperplasia (BPH). This study was undertaken to assess the clinical efficacy and safety of TmLRP-TT for the treatment of BPH patients with previously negative transrectal prostate biopsy. A prospective analysis of 51 patients with previously negative transrectal prostate biopsy who underwent surgical treatment using TmLRP-TT was performed from December 2011 to December 2013. Preoperative status, surgical details, and perioperative complications were recorded. The follow-up outcome was evaluated with subjective and objective tests at 1 and 6 months. TmLRP-TT was successfully completed in all patients. Mean prostate volume, operative duration, and catheterization time were 93.3 ± 37.9 ml, 69.5 ± 39.5 min, and 6.5 ± 1.3 days, respectively. The mean International Prostate Symptom Score, quality of life score, maximum urinary flow rate, and post-void residual urine volume changed notably at 6-month follow-up (22.5 ± 6.9 vs 6.1 ± 3.2, 4.8 ± 1.3 vs 1.1 ± 0.9, 7.3 ± 4.5 vs 18.9 ± 7.1 ml s-1 , and 148.7 ± 168.7 vs 28.4 ± 17.9 ml). Two (3.9%) patients required blood transfusion perioperatively, while 3 (5.9%) patients experienced transient hematuria postoperatively, and 2 (3.9%) patients received 3 days recatheterization due to clot retention. TmLRP-TT is a safe and effective minimally invasive technique for patients with previously negative transrectal prostate biopsy during the 6-month follow-up. This promising technology may be a feasible surgical method for previously negative transrectal prostate biopsy in the future.
[Mh] Termos MeSH primário: Terapia a Laser/métodos
Lasers de Estado Sólido/uso terapêutico
Hiperplasia Prostática/cirurgia
Túlio
Ressecção Transuretral da Próstata/métodos
[Mh] Termos MeSH secundário: Idoso
Biópsia com Agulha de Grande Calibre
Seres Humanos
Masculino
Meia-Idade
Duração da Cirurgia
Tamanho do Órgão
Estudos Prospectivos
Próstata/patologia
Próstata/cirurgia
Hiperplasia Prostática/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8RKC5ATI4P (Thulium)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160107
[St] Status:MEDLINE
[do] DOI:10.4103/1008-682X.168790


  10 / 487 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27928808
[Au] Autor:Xie T; Lai P; Luo M; Xu Y
[Ad] Endereço:Department of Urology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, People's Republic of China.
[Ti] Título:The Effectiveness and Safety of Transurethral (Bipolar) Plasmakinetic Resection of Prostate Combined with Thulium Laser for Large Benign Prostatic Hyperplasia (>80ml).
[So] Source:Urol J;13(6):2889-2892, 2016 12 08.
[Is] ISSN:1735-546X
[Cp] País de publicação:Iran
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the clinical curative effect and safety of transurethral (bipolar) plasmakinetic resection of theprostate (PKRP) combined with thulium laser in the treatment of large prostates (> 80mL). MATERIALS AND METHODS: From January 2014 to December 2015, 61 patients with benign prostate hyperplasia(BPH) were treated with PKRP combined with thulium laser (n = 25) or PKRP only (n = 36). We retrospectivelyanalyzed the perioperative status of patients status during 3-month follow-up. RESULTS: There was no significant difference between the two groups before treatment (P > .05). PKRP combinedwith thulium laser was significantly superior to PKRP in terms of surgical duration, intraoperative blood loss,postoperative bladder washing time, postoperative complications and time of hospital stay (P < .05). There were nosignificant improvements at international prostatic symptom score (IPSS), quality of life (QOL), maximum flowrate (Qmax), and post-void residual (PVR) urine between two groups after 3 months (P > .05). CONCLUSION: PKRP combined with thulium laser is superior than PKRP only for better surgical duration, lessbleeding, higher efficiency and much quicker recovery. It may be a better choice for the treatment of BPH withlarge prostate (> 80mL).
[Mh] Termos MeSH primário: Eletrocirurgia
Terapia a Laser
Hiperplasia Prostática/patologia
Hiperplasia Prostática/cirurgia
Ressecção Transuretral da Próstata/métodos
[Mh] Termos MeSH secundário: Idoso
Terapia Combinada
Eletrocirurgia/efeitos adversos
Seguimentos
Seres Humanos
Terapia a Laser/efeitos adversos
Masculino
Estudos Retrospectivos
Túlio
Ressecção Transuretral da Próstata/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8RKC5ATI4P (Thulium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170412
[Lr] Data última revisão:
170412
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161209
[St] Status:MEDLINE



página 1 de 49 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde